Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Russian Bear who wrote (1111)	9/15/1998 1:11:00 PM
From: David Cathcart	Respond to of 1826

RB, <<MGI will be launching two other PII trials (one for ovarian and another for pancreatic cancer) by the end of 1998>> I find it very interesting, perhaps very encouraging, that MGI Pharma is sponsoring two additional phase II trials. Could this mean that they are seeing compelling efficacy results in phase I? In that they are already conducting one phase II trial, and the NCI has committed to sponsoring eleven others, something must be telling them that they like their chances for ovarian and pancreatic cancers. Interesting times. David